Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [CytoScanHD_Array]

ABSTRACT: Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [CytoScanHD_Array]

PROVIDER: PRJNA546537 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications

Project description:Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications

| PRJNA546530 | ENA

Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [HTA-2_0]

Project description:Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [HTA-2_0]

| PRJNA546536 | ENA

Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [Infinium MethylationEPIC]

Project description:Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [Infinium MethylationEPIC]

| PRJNA547826 | ENA

Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [RNA-seq]

Project description:Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [RNA-seq]

| PRJNA549741 | ENA

Epigenetic footprint of hepatoblastoma defines a novel integrative molecular classification with clinical implications [CytoScanHD_Array]

Project description:Hepatoblastoma (HB) is the predominant pediatric liver cancer with limited therapeutic options for patients with aggressive tumors. Nevertheless, it is a rare disease. Here, we performed a high-throughput molecular study of 32 patients with HB and major findings were validated in additional 80 cases. We unveiled an epigenetic footprint including downregulation of RNA-editing, hyperediting of the tumor suppressor BLCAP,14q32 DLK1-DIO3 locus overexpression, DNA hypomethylation and CpG island hypermethylation. Based on these findings, we defined an integrative molecular classification of HB that improve current clinical stratification, and identified CHKA as a therapeutic target for the poor prognostic subclass.

2020-03-23 | GSE132218 | GEO